Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Fortuny

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Aging Clinical and Experimental Research|June 24, 2021
Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel diseaseMargalida Calafat, Carlos González-Muñoza, Marta Fortuny, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on ImmunotherapyMarta Fortuny, Leonardo G da Fonseca, Manon Allaire, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Aging Clinical and Experimental Research|June 24, 2021
Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel diseaseMargalida Calafat, Carlos González-Muñoza, Marta Fortuny, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2025
Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomesMarta Fortuny, Marta García-Calonge, Óscar Arrabal, et al.
Alimentary Pharmacology & Therapeutics|February 23, 2026
Clinical Trial: Early Nivolumab Addition to Regorafenib in Patients With Hepatocellular Carcinoma in Second-Line (The GOING Trial)Marco Sanduzzi-Zamparelli, Ana Matilla, José Luis Lledo, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 12, 2025
Breaking Barriers for Intensive Care Admission in Patients With Advanced HCC on ImmunotherapyMarta Fortuny, Leonardo G da Fonseca, Manon Allaire, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Pageof 2